| Management target | Revenue 15.0% FY27 |
|---|
| Revenue growth | 22% YoY to ₹441 Cr, driven by strong chronic segment performance. |
|---|---|
| Margins | EBITDA margin stable at 21.7%; PAT growth slowed by higher depreciation. |
| Demand visibility | Strong, specifically in chronic therapies like IVF and cardio-diabeto. |
| Management confidence | Highly confident, emphasizing consistent outperformance versus the broader Indian pharma market. |
Growth
Revenue grew 22% YoY to ₹441 Cr; Chronic segment grew 29%, significantly outperforming the market's 15%.
Outlook
Management guides for 15% revenue and 20% PAT growth, maintaining a 1.5x market outperformance ratio.
Risks
Higher depreciation from new facilities and acquisitions is currently tempering PAT growth relative to revenue.
Last quarter's promises, checked
Delivered
- Guided 15% FY27 revenue growth → delivered 22% YoY to ₹441 Cr (= BEAT)
Partly delivered
- Guided EBITDA margin held in similar range (~22%) → delivered 21.7% (= PARTIAL)
Missed
- Guided 20% FY27 PAT growth → delivered 15.3% YoY, ₹60 Cr (= MISS)
- Guided Semaglutide market ₹1,500–1,800 Cr → now ₹1,200–1,400 Cr first-year (= MISS)
Earnings Call Transcript filed with NSE, NSE: CORONA. Summary written with AI assistance from the document.
Corona Remedies Ltd: key numbers
- Share price
- ₹2,149.60
- Market cap
- ₹13,147 Cr
- Revenue (annual)
- ₹1,403 Cr
- Net profit (annual)
- ₹185.1 Cr
- P/E (TTM)
- 63.5×Sector 45.9×
- Promoter holding
- 69.00%+0.00% QoQ
- FII holding
- 4.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Corona Remedies Ltd
All →Corona Remedies Investor Presentation: Key Takeaways
Q2FY27 revenue ₹441.2Cr (+22.2%), PAT ₹60.3Cr (+15.3%); H1 revenue ₹863.6Cr (+22.0%), PAT ₹120.4Cr (+22.2%). Chronic-led growth, outpacing IPM.
Corona Remedies Results Update
Corona Remedies released unaudited Q2 and H1 FY27 results highlights via press release. Revenue grew 22% year on year, with EBITDA and PAT also rising.
Corona Remedies Q2 FY27 Results: Net Profit ₹60.3 Cr, Up 15.3% YoY
Corona Remedies Ltd reported revenue from operations of ₹441.2 Cr (+22.2% YoY) and net profit of ₹60.3 Cr (+15.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹60.3 Cr · +15.3% YoY
Corona Remedies Business Update
Corona Remedies received GMP Compliance Certification from Brazil's ANVISA for its OSD and Hormone facilities in Ahmedabad. This validates export eligibility to the Brazilian pharmaceutical market.
Corona Remedies Board Meeting Date
Corona Remedies Limited will hold a board meeting on October 30, 2026. The board will consider unaudited financial results for the quarter and half-year ended September 30, 2026.
Corona Remedies Other Announcement
This filing contains quarterly shareholding pattern disclosures for Corona Remedies Ltd. It provides details on share distribution as required by regulatory compliance norms.